Vascular Endothelial Growth Inhibitor (VEGI), also known as TNFSF15, is a member of the tumor necrosis factor (TNF) superfamily. It plays a critical role in regulating angiogenesis, inflammation, and immune responses. VEGI is primarily expressed in endothelial cells and functions as an endogenous inhibitor of blood vessel formation, making it a significant factor in cancer research and therapeutic applications (NCBI).
Structural Characteristics and Function of VEGI
VEGI is a cytokine that binds to its receptor, Death Receptor 3 (DR3), to regulate vascular homeostasis and immune function. Studies indicate that VEGI inhibits endothelial cell proliferation and migration, effectively countering excessive angiogenesis seen in tumor growth and inflammatory diseases. VEGI can also induce apoptosis in endothelial cells, further supporting its role in anti-angiogenesis (National Human Genome Research Institute).
The molecular structure of VEGI consists of conserved TNF superfamily domains, enabling its interaction with signaling receptors and downstream pathways. Researchers have identified different isoforms of VEGI, including VEGI-174, VEGI-192, and VEGI-251, each exhibiting distinct biological effects on endothelial cells and immune modulation.
Clinical Significance of VEGI
VEGI has been implicated in various physiological and pathological conditions, including:
- Tumor angiogenesis suppression – VEGI acts as a natural inhibitor of neovascularization, making it a promising target in anti-cancer therapy.
- Inflammatory diseases – Dysregulation of VEGI expression is associated with autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease.
- Wound healing and tissue regeneration – VEGI modulates vascular remodeling, influencing tissue repair processes.
- Cardiovascular health – Altered VEGI levels have been linked to endothelial dysfunction and atherosclerosis, suggesting its role in vascular homeostasis.
Research suggests that manipulating VEGI expression could provide therapeutic strategies for diseases where abnormal angiogenesis is a factor (NIH Genetic and Rare Diseases Information Center).
Role of VEGI in Cancer and Disease Progression
VEGI plays a dual role in cancer biology:
- As an anti-angiogenic agent, VEGI inhibits tumor vascularization, preventing nutrient supply to tumor cells.
- VEGI modulates immune cell activity, influencing the tumor microenvironment and immune surveillance.
- VEGI expression is often downregulated in various cancers, including colorectal, breast, and lung cancers, making it a potential biomarker for tumor progression.
- VEGI’s role in metastasis – Some studies indicate that VEGI may suppress metastatic spread by modulating extracellular matrix interactions (Cancer.gov).
VEGI (VEGI/1283), CF488A Conjugate, 0.1mg/mL Antibody: Applications in Research and Medicine
The CF488A-conjugated VEGI antibody is a crucial tool in molecular and cellular research. Key applications include:
- Western blotting – To detect and quantify VEGI protein expression in different tissues (Protein Atlas).
- Immunohistochemistry (IHC) and immunofluorescence – For visualizing VEGI localization in normal and pathological tissues (Human Protein Atlas).
- Flow cytometry – To assess VEGI expression in different cell populations using fluorescent tagging.
- ELISA and cytokine profiling – To quantify VEGI levels in biological fluids.
- Angiogenesis assays – To study VEGI-mediated endothelial cell function and tumor progression.
- Animal model studies – VEGI antibodies are used in preclinical research to explore its effects on tumor growth inhibition.
- Drug development – Investigating VEGI as a target for small-molecule inhibitors and therapeutic antibodies.
These applications make VEGI antibodies invaluable for research in oncology, vascular biology, and immunology.
Current Research and Future Directions
Ongoing studies continue to explore VEGI’s role in various diseases. Some key research areas include:
- VEGI as a therapeutic target for cancer treatment – Developing drugs that enhance VEGI expression to inhibit tumor angiogenesis.
- VEGI in autoimmune diseases – Investigating its regulatory role in immune disorders.
- VEGI and cardiovascular diseases – Understanding its function in endothelial dysfunction and vascular inflammation.
- VEGI-based biomarkers for early cancer detection – Exploring VEGI levels as diagnostic tools for malignancies.
- Gene therapy approaches targeting VEGI – Research on CRISPR/Cas9-mediated modulation of VEGI expression.
- Combination therapies – Exploring VEGI inhibitors alongside immune checkpoint inhibitors for improved cancer treatment.
Conclusion
VEGI is a crucial regulator of angiogenesis and immune function, with significant implications in cancer, inflammation, and vascular biology. The VEGI (VEGI/1283), CF488A Conjugate, 0.1mg/mL antibody serves as a powerful tool for researchers studying VEGI’s role in health and disease. As research progresses, VEGI may emerge as a promising target for novel therapeutic interventions.
For researchers and clinicians seeking authoritative information on VEGI-related studies, resources such as NIH, PubMed, and Genomics England provide extensive literature and data on this critical protein.


